PH12021551398A1 - Fusion protein constructs for complement associated disease - Google Patents

Fusion protein constructs for complement associated disease

Info

Publication number
PH12021551398A1
PH12021551398A1 PH1/2021/551398A PH12021551398A PH12021551398A1 PH 12021551398 A1 PH12021551398 A1 PH 12021551398A1 PH 12021551398 A PH12021551398 A PH 12021551398A PH 12021551398 A1 PH12021551398 A1 PH 12021551398A1
Authority
PH
Philippines
Prior art keywords
fusion protein
protein constructs
complement
associated disease
complement associated
Prior art date
Application number
PH1/2021/551398A
Other languages
English (en)
Inventor
Justin Andrew Caravella
Michael Steven Curtis
Kelly C Fahnoe
Vernon Michael Holers
Cheng Ran Huang
Susan L Kalled
Ellen Garber Stark
Michael Storek
Frederick Robbins Taylor
Shelia Marie Violette
Original Assignee
Q32 Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Q32 Bio Inc filed Critical Q32 Bio Inc
Publication of PH12021551398A1 publication Critical patent/PH12021551398A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PH1/2021/551398A 2018-12-11 2019-12-11 Fusion protein constructs for complement associated disease PH12021551398A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862778014P 2018-12-11 2018-12-11
PCT/US2019/065741 WO2020123662A2 (en) 2018-12-11 2019-12-11 Fusion protein constructs for complement associated disease

Publications (1)

Publication Number Publication Date
PH12021551398A1 true PH12021551398A1 (en) 2022-11-07

Family

ID=71076704

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2021/551398A PH12021551398A1 (en) 2018-12-11 2019-12-11 Fusion protein constructs for complement associated disease

Country Status (14)

Country Link
US (4) US11053305B2 (enExample)
EP (1) EP3893916A4 (enExample)
JP (3) JP7444886B2 (enExample)
KR (2) KR20250021629A (enExample)
CN (1) CN113660944A (enExample)
AU (2) AU2019398214C1 (enExample)
GB (1) GB2583560A (enExample)
IL (1) IL283841A (enExample)
MA (1) MA54468A (enExample)
MX (2) MX2021006930A (enExample)
MY (1) MY209796A (enExample)
PH (1) PH12021551398A1 (enExample)
SG (1) SG11202106073QA (enExample)
WO (1) WO2020123662A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3394089T (lt) * 2015-12-23 2021-11-25 eleva GmbH Polipeptidai, skirti komplemento aktyvacijos inhibicijai
AU2017345560C1 (en) * 2016-10-20 2025-04-17 President And Fellows Of Harvard College In vitro and cell based assays for measuring the activity of botulinum neurotoxins
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
TW202003576A (zh) * 2018-05-10 2020-01-16 美商艾博視訊有限公司 活化cd40之單株抗體及其用途
MX2021006930A (es) * 2018-12-11 2021-11-17 Q32 Bio Inc Construcciones de proteínas de fusión para enfermedades asociadas al complemento.
KR20220019806A (ko) * 2019-06-12 2022-02-17 씨에스엘 이노베이션 피티와이 엘티디 가용성 보체 수용체 1형 변이체 접합체 및 이의 용도
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
WO2021247487A1 (en) * 2020-06-01 2021-12-09 Medical University Of South Carolina Recombinant fusion proteins targeting p-selectin, and methods of use thereof for treating diseases and disorders
WO2021257480A2 (en) 2020-06-14 2021-12-23 Catalyst Biosciences, Inc. Complement factor i-related compositions and methods
WO2022010830A2 (en) * 2020-07-06 2022-01-13 President And Fellows Of Harvard College Histamine binding polypeptides and uses thereof
IL301202A (en) * 2020-09-10 2023-05-01 Vascular Biogenics Ltd Antibodies against MOTILE SPERM DOMAIN CONTAINING PROTEIN 2 and methods of using them
EP4259193A4 (en) * 2020-12-09 2025-01-15 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
US12522657B2 (en) 2021-06-22 2026-01-13 The General Hospital Corporation Therapeutic targeting of Cadherin 11 in cancer
GB202203627D0 (en) 2022-03-16 2022-04-27 Univ Manchester Agents for treating complement-related disorders
CN114778418B (zh) * 2022-06-17 2022-09-27 深圳安侣医学科技有限公司 基于显微放大数字图像的血红蛋白分析方法及系统
US20260077039A1 (en) * 2022-08-30 2026-03-19 Longbio Pharma (Suzhou) Co., Ltd. Anti-human complement c5 antibody and fusion protein thereof
WO2024099320A1 (zh) * 2022-11-10 2024-05-16 天辰生物医药(苏州)有限公司 补体抑制杂合蛋白突变体及其抗体融合蛋白
WO2024146953A1 (en) 2023-01-05 2024-07-11 Complement Therapeutics Limited Agents and methods for treating complement diseases
IL324504A (en) * 2023-05-23 2026-01-01 4D Molecular Therapeutics Inc Antibodies that inhibit the complement system
WO2025054327A1 (en) * 2023-09-05 2025-03-13 The Regents Of The University Of Colorado, A Body Corporate Constructs, compositions, and methods for reducing hypersensitivity reactions to therapeutic agents
AU2024373907A1 (en) * 2023-10-30 2026-05-14 Akebia Therapeutics, Inc. Treatment of anca-associated vasculitis
AU2024370039A1 (en) * 2023-10-30 2026-05-28 Akebia Therapeutics, Inc. Treatment of complement-associated renal diseases
AU2024384696A1 (en) * 2023-11-24 2026-06-04 Universität Ulm Complement modulator
EP4559472A1 (en) * 2023-11-24 2025-05-28 Universität Ulm Complement modulator
TW202606662A (zh) 2024-04-26 2026-02-16 美商美國禮來大藥廠 蛋白質酪胺酸激酶7抗體及抗體藥物結合物
CN118373913B (zh) * 2024-05-08 2024-11-01 上海百英生物科技股份有限公司 一种抗人Tim-3单克隆抗体及其制备方法
CN118878672A (zh) * 2024-08-01 2024-11-01 河北康立德生物科技有限公司 一种抗曲霉半乳甘露聚糖单克隆抗体、试剂盒及其应用
CN122255261A (zh) * 2024-12-10 2026-06-23 中国医学科学院病原生物学研究所 检测a35r蛋白的单克隆抗体及其应用
CN119431565B (zh) * 2025-01-10 2025-04-08 成都迈科康生物科技有限公司 一种抗hpv16型e6蛋白和e7蛋白的抗体、检测产品及其应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US20010018051A1 (en) 1990-04-09 2001-08-30 White David James Graham Inhibition of allograft and concordant xenograft rejection
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5679345A (en) 1994-06-02 1997-10-21 The Johns Hopkins University Method for preventing complement-dependent rejection of organ or tissue transplants
GB9614871D0 (en) 1996-07-15 1996-09-04 Smithkline Beecham Plc Compounds
AU756490B2 (en) 1997-08-26 2003-01-16 Abgenix, Inc. A process for inhibiting complement activation via the alternative pathway
EP3056516A1 (en) 1998-02-20 2016-08-17 Genentech, Inc. Inhibitors of complement activation
WO2001080883A1 (en) * 2000-04-26 2001-11-01 Elusys Therapeutics, Inc. Bispecific molecules and uses thereof
EP1186299A1 (en) 2000-09-12 2002-03-13 Universitair Medisch Centrum Utrecht The diagnosis, prevention, and/or succesful treatment of atherosclerosis, infectious diseases, and disturbances in the immune system
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
CA2471938A1 (en) * 2001-12-28 2003-07-17 Kyowa Hakko Kogyo Co., Ltd. Agent for treating arthritis
EP1594541A4 (en) 2003-02-21 2007-03-28 Rikshospitalet Radiumhospitale METHOD AND COMPOSITIONS FOR TREATING MECONIUM ASPIRATION SYNDROME
AU2004216176B2 (en) 2003-02-21 2008-04-03 Genentech, Inc. Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
HUE034760T2 (en) 2003-05-12 2018-02-28 Helion Biotech Aps Masp-2-T binding antibodies
WO2005027965A1 (en) 2003-09-24 2005-03-31 Peter Krammer Antibodies against annexins, use thereof for therapy and diagnosis. use of annexins for therapy and diagnosis.
WO2005063815A2 (en) * 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
BRPI0506629A (pt) 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
WO2006042252A2 (en) * 2004-10-08 2006-04-20 Potentia Pharmeceuticals, Inc. Viral complement control proteins for eye disorders
TW200726845A (en) 2006-01-02 2007-07-16 Nat Defense Medical Ct Biomarker molecular of renal illness and detecting method for the same
US20110014270A1 (en) 2006-03-27 2011-01-20 The Regents Of The University Of Colorado Prevention and treatment of ischemia-reperfusion injury and related conditions
CN106084055A (zh) 2006-11-02 2016-11-09 健泰科生物技术公司 人源化的抗‑d因子抗体
AU2008262048B2 (en) 2007-06-07 2013-09-26 Genentech, Inc. C3b antibodies and methods for the prevention and treatment of complement- associated disorders
US8981060B2 (en) 2007-08-27 2015-03-17 Novelmed Therapuetics, Inc. Method of inhibiting complement activation with factor Bb specific antibodies
CL2008003241A1 (es) 2007-11-02 2009-07-31 Novartis Ag Molecula de enlace que comprende una porcion de enlace de antigeno que se enlaza con un neoepitopo de c3b; composicion farmaceutica que la comprende; y su uso para tratar trastornos oculares
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
US8937046B2 (en) 2008-09-22 2015-01-20 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
US20100291106A1 (en) 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
EP3150635A3 (en) 2009-10-16 2017-06-21 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
CN102958535A (zh) 2009-11-05 2013-03-06 亚力史剑桥公司 阵发性夜间血红蛋白尿、溶血性贫血和涉及血管内和血管外溶血的疾病状态的治疗
BR112012033119A2 (pt) * 2010-06-22 2016-10-25 Univ Colorado Regents anticorpos para o fragamento c3d do componente do complemento 3.
TW201241008A (en) 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
US20120122107A1 (en) 2010-11-16 2012-05-17 Aarhus Universitet Homeostatic multidomain protein, and uses for it
WO2012075023A2 (en) 2010-11-29 2012-06-07 Novelmed Therapeutics, Inc. Neoantibodies for diagnosing tissue injury
TWI622597B (zh) * 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
BR112014013205A2 (pt) * 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
PT2861246T (pt) 2012-06-18 2021-04-05 Univ Leicester Composições e métodos para inibir masp-1 e/ou masp-2 e/ou masp-3 para o tratamento de várias doenças e perturbações
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
CA2899034A1 (en) 2013-01-23 2014-07-31 Musc Foundation For Research Development Targeting constructs based on natural antibodies and uses thereof
BR112016011195A2 (pt) * 2013-11-18 2017-09-19 Rubius Therapeutics Inc Células eritroides enucleadas e seus métodos de fabricação, composição farmacêutica e seu uso, uso de uma população de células eritroides, biorreator, mistura de células e dispositivo médico
WO2015105973A1 (en) * 2014-01-08 2015-07-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ANTIBODY TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF
CN106456744A (zh) * 2014-04-01 2017-02-22 鲁比厄斯治疗法股份有限公司 用于免疫调节的方法和组合物
AU2015269348C1 (en) 2014-06-05 2021-11-18 The Regents Of The University Of Colorado, A Body Corporate MAp44 polypeptides and constructs based on natural antibodies and uses thereof
AR103488A1 (es) * 2015-01-23 2017-05-10 Sanofi Sa Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
MX2021006930A (es) 2018-12-11 2021-11-17 Q32 Bio Inc Construcciones de proteínas de fusión para enfermedades asociadas al complemento.

Also Published As

Publication number Publication date
KR20250021629A (ko) 2025-02-13
MY209796A (en) 2025-08-05
US11879008B2 (en) 2024-01-23
KR20210148076A (ko) 2021-12-07
US20200181249A1 (en) 2020-06-11
JP7444886B2 (ja) 2024-03-06
US11053305B2 (en) 2021-07-06
CA3123004A1 (en) 2020-06-18
MX2021006930A (es) 2021-11-17
SG11202106073QA (en) 2021-07-29
WO2020123662A2 (en) 2020-06-18
AU2019398214C1 (en) 2024-03-28
US11053306B2 (en) 2021-07-06
IL283841A (en) 2021-07-29
JP7811315B2 (ja) 2026-02-05
MA54468A (fr) 2022-04-13
MX2026002955A (es) 2026-05-04
JP2022512234A (ja) 2022-02-02
US20210309728A1 (en) 2021-10-07
US20240301043A1 (en) 2024-09-12
KR102762828B1 (ko) 2025-02-05
AU2024201109A1 (en) 2024-03-14
AU2019398214A1 (en) 2021-07-01
CN113660944A (zh) 2021-11-16
JP2026053563A (ja) 2026-03-25
JP2024059791A (ja) 2024-05-01
GB2583560A (en) 2020-11-04
EP3893916A4 (en) 2023-03-29
GB202001360D0 (en) 2020-03-18
EP3893916A2 (en) 2021-10-20
WO2020123662A3 (en) 2020-07-23
US20210009669A1 (en) 2021-01-14
AU2019398214B2 (en) 2023-11-23

Similar Documents

Publication Publication Date Title
MY209796A (en) Fusion protein constructs for complement associated disease
WO2019241430A3 (en) Antibody-oligonucleotide conjugates
SA519402358B1 (ar) Ccr7 مترافقات عقار جسم مضاد لـ
IL280467A (en) Antibody constructs for cldn18.2 and cd3
PH12020550860A1 (en) Anti-trem2 antibodies and related methods
MX2023005375A (es) Anticuerpos trivalentes biespecificos unidos a claudina 6 o claudina 18.2 y cd3 para el tratamiento de enfermedades de cancer que expresan claudina.
MX2021006681A (es) Anticuerpos anti-claudina y usos de los mismos.
AU2019415848A8 (en) Claudin18.2 binding moieties and uses thereof
NZ782442A (en) Antibodies that bind cd39 and uses thereof
MX2024007724A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado
MX2020002921A (es) Anticuerpos para claudin6 y métodos para tratar el cáncer.
MX2020000960A (es) Anticuerpos anti-tigit.
MX2021004588A (es) Anticuerpo anti-cldn18.2 y sus usos.
MX2021015888A (es) Fusión de un anticuerpo que se une a cea y 4-1bbl.
EP4374922A3 (en) Anti-c5 antibodies and uses thereof
WO2019195623A3 (en) Heterodimeric antibodies that bind fibroblast activation protein
TN2019000294A1 (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
CR20170383A (es) Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
AR105267A1 (es) Anticuerpos de unión a tau
MX2021011330A (es) Anticuerpos de claudina-6 y conjugados de fármacos.
EP3892634A4 (en) ANTI-CD40 ANTIBODIES, ANTIGEN BINDING FRAGMENT AND PHARMACEUTICAL USE THEREOF
MX2020008718A (es) Anticuerpos de union a bcma y usos de los mismos.
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
ZA202200906B (en) Anti-her2/anti-4-1bb bispecific antibody and use thereof
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use